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A single intraperitoneal  injection of rats with an aqueous suspension of peptid- 
oglycan-polysaccharide polymers derived from group A  streptococci (PG-APS) 1 
or from certain other bacterial species, results in acute joint inflammation that is 
followed by a  chronic,  recurrent,  erosive  arthritis  (1-4).  The  histologic  and 
radioiogic features of this experimental disease resemble those of human rheu- 
matoid arthritis.  The clinical course is characterized by repeated remissions and 
exacerbations, and eventual progression to ankylosis, fibrosis, and loss of function 
(1, 5). The severity and course of arthritis  is influenced by the sex and genetic 
background of the rat (3, 6). The persistence of cell wall in chronically inflammed 
tissues is important in PG-APS-induced arthritis and in the various other animal 
models of chronic inflammation induced by PG-APS (1, 7-1 1). 
The size of the PG-APS polymers is important in determining the course and 
severity  of arthritis  in  the  rat  model  (12,  13).  Differential  centrifugation  of 
sonicated cell wall preparations has been used to obtain families of PG-APS with 
different average molecular weight and arthropathic potential (12). The smaller 
fragments, which have an average molecular weight of 5.3 x  106, induce a severe 
acute arthritis  but  relatively  little  chronic  disease.  Fragments  of intermediate 
size, with an average molecular weight of 5.0 ×  107, cause moderate acute and 
severe chronic arthritis.  Recently, it has been demonstrated that PG-APS can be 
degraded in vitro with mutanolysin (M-1), or phage-associated lysin, to fragments 
of a  molecular weight <5.0  x  106. When injected intraperitoneally  or intrave- 
nously into rats,  these enzymatic digests cannot induce arthritis;  however, they 
cause a rapid, transient edema of the limbs (13). 
Mutanolysin is a muramidase derived from Streptomyces globisporus. It has been 
used to digest cell walls from a  number of bacterial  species (14-17),  since it is 
specific for the  ~/  1-4  linkage  of N-acetyimuramyl-N-acetyl glucosamine  in  the 
glycan backbone of peptidoglycan.  The  finding that  PG-APS digested in vitro 
with mutanolysin loses its arthropathic  potential prompted us to investigate the 
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1360  J. ExP. MED. © The Rockefeller  University  Press • 0022-1007/84/11/1360/15 $1.00 
Volume 160  November 1984  1360-1374 JANUSZ  ET  AL.  1361 
in vivo effect of this enzyme on PG-APS-induced arthritis. We found that a single 
intravenous injection of mutanolysin, even when given at the peak of acute joint 
inflammation, prevented the development of recurrent, chronic erosive arthritis. 
Materials and  Methods 
Preparation of Cell Wall.  Purified cell walls  were prepared from group A,  type  3, 
strain D-58 streptococci as previously described (12). Briefly, streptococci were grown in 
Todd Hewitt broth (BBL Microbiology Systems, Cockeysville, MD), harvested, washed in 
sterile phosphate-buffered saline (PBS), and disrupted in a Braun MSK shaker (Bronwill 
Scientific Inc., Rochester, NY). Intact cells were removed by centrifugation at 2,000 g for 
30 min. Cell walls were pelleted by centrifugation at  10,000 g for 30 min and further 
purified by sequential treatment with RNase, trypsin, and papain, followed by chloroform- 
methanol extraction. The cell walls were then washed with water, dialysed against water, 
and lyophilized. The lyophilized cell walls were resuspended to 20 mg/ml in PBS and 
sonicated for 70  min  in a  Branson sonifier (Branson Sonic Power Co.,  Danbury, CT) 
using a  1/2 inch probe in a sealed 40-ml stainless steel cup that was cooled with a water 
jacket. The sonicated cell wall was centrifuged at 10,000 g for 30 min, and the supernatant 
collected for injection into rats. 
Mutanolysin Preparations.  The purified M-1 fraction of mutanolysin and crude mutan- 
olysin were obtained from K. Yokagawa (Dianippon Pharmaceuticals, Ltd., Osaka, Japan) 
or purchased from Miles Laboratories, Inc., Elkhart, IN. The purity of the mutanolysin 
preparations was tested by analytical isoelectric focusing (IEF) using 5% polyacrylamide 
gels, Servalytes 2-11 (Serva Biochemicais, Heidelberg, Federal Republic of Germany), and 
an LKB multiphor flat-bed apparatus (LKB Produkter, Bromma, Sweden). The protein 
standards were Serva protein test mixture 9 (Serva Biochemicals). When the gels were 
focused at a constant power of 4 W for 2 h, purified mutanolysin showed a single cathodal 
migrating band, while crude mutanolysin showed at least five major bands. When an IEF 
gel was run under the same conditions for 70 min, to avoid gradient drift and to increase 
resolution in the alkaline region of the gel, an additional band was seen in the purified 
mutanolysin preparations (Fig.  1). 
Proteolytic activity has been reported to co-migrate with M-1 on IEF gels, but it can be 
separated  from the  muramidase  by ion exchange chromatography on  CM  Sephadex, 
which was the procedure involved in the purification of the mutanolysin used in this study 
(14, 15,  18). Proteolytic activity in the mutanolysin preparations was measured using the 
Azocoll assay (Calbiochem-Behring Corp., La Jolla, CA), as described by Siegel et al. (18). 
The purified M-1  preparations had no detectable proteolytic activity, while the crude 
mutanolysin preparation was heavily contaminated. 
Mutanolysin was also purified in our laboratory from crude enzyme by preparative IEF 
in  a  granulated  gel  bed  (Ultradex;  LKB  Produkter) on  an  LKB  multiphor  flat-bed 
apparatus. The procedure followed LKB application note 198, except that Servalytes 3- 
10 (Serva Biochemicals) were used in place of LKB ampholines. The mutanolysin purified 
by IEF was free of proteolytic activity and possessed the same in vivo effect on PG-APS- 
induced arthritis, when administered immediately after cell wall, as M-1 purified by the 
method of Yokagawa et al. (14,  15). Immediately before injection into rats, mutanolysin 
preparations were  solubilized by sonication for 30  s  using a  9  kcycle sonic oscillator 
(Raytheon Co., Waltham, MA). 
Animals.  Inbred female Lewis rats were obtained from Charles River Breeding Lab- 
oratories, Wilmington, MA. They weighed 100-120 g at the time of PG-APS injection. 
The rats were housed two to three per cage and fed Purina rat chow and water ad libitum. 
Scoring of Edema and Arthritis.  Arthritis was scored on an arbitrary scale of 0-4, as 
described previously (1), with a maximum score of 16 per rat. The chronic erosive nature 
of the arthritis was confirmed by x ray (5) and by histological evaluation. The transient 
edema that appeared in the front and hind limbs of rats given M-1 immediately after PG- 
APS was estimated by a visual assessment of swelling over the first 10 h postinjection. An 
arbitrary scale of 0-4 was also used for each limb; therefore, the maximum score per rat 1362  TREATMENT  OF  ARTHRITIS IN  RATS  WITH  MUTANOLYSIN 
Fmu~tE  1.  IEF of several mutanolysin preparations.  10-~g samples were applied in the acidic 
region of the gel and allowed to migrate towards the basic region. (A) Protein standards with 
isoelectric points ranging from 3.5 to 10.6. (B) Crude mutanolysin. (C and D) Two different 
purified preparations  of mutanolysin. 
was 16. In a previous study (13,  19), using PG-APS digested in vitro with mutanolysin, or 
purified  group  A  polysaccharide,  we  found  an  excellent  correlation  between  clinical 
scoring and the accumulation of ~2sI human serum albumin in the limbs. 
Histology.  Rat tissues were fixed in  10% formalin, and paraffin sections were stained 
with hematoxylin and eosin (HE) and by periodic acid-Schiff digest method. The tissues 
of the ankles and hind feet were decalcified in formic acid-sodium citrate solution for 5- 
14 d after fixation. Tissue sections from two to eight rats from each group were examined. 
Quantitation of Cell  Wall in  Tissue Extracts.  An enzyme-linked immunosorbent assay 
(ELISA) modification of the solid phase radioimmunoassay developed by Eisenberg et ai. 
(9) was used to quantitate the amount of PG-APS in rat blood, liver, spleen, and limbs. 
Briefly, tissue samples were frozen in liquid nitrogen, crushed, and extracted with 0.2 M 
Tris buffer containing  1% Tween 80 and 5 mg/ml collagenase (Sigma Chemical Co., St. 
Louis, MO) for 6 h at 37 ° C. Supernatants of the extracts were added to 96-well microtiter 
plates previously coated with affinity-purified anti-group A antibody. Biotinylated affinity- 
purified anti-group A antibody was then added, followed by avidin alkaline phosphatase. 
The color reaction was developed using p-nitrophenyl phosphate substrate (Sigma Chem- 
ical Co.) and monitored by an automated Microelisa reader (model MR 580;  Dynatech 
Laboratories, Inc., Alexandria, VA). 
Chemical Analysis.  Cell wall preparations were analyzed by gas-liquid chromatography. 
N-acetyl-muramic acid, N-acetyl-glucosamine, rhamnose, and glucose were assayed as their 
alditol acetates (20). Samples were hydrolyzed under vacuum for 3 h at  100°C with 2 N 
sulfuric acid before derivatization. Rhamnose was also assayed using the method of Dische 
and Shettles (2 I). JANUSZ ET  AL.  1363 
Results 
Mutanolysin Can Prevent PG-APS-induced Arthritis.  In the initial experiment, 
18 rats were injected intraperitoneally with an arthropathic dose of PG-APS (20 
#g rhamnose/gram body weight) and immediately thereafter injected with 0.4 
mg i.v. of mutanolysin. A control group of 18 rats was injected intraperitoneally 
with PG-APS followed by 0.4 ml of PBS i.v. Another control group of three rats 
was  injected  with  PBS  i.p.  and  0.4  mg  mutanolysin  i.v.  The  control  group 
injected with PG-APS and PBS developed the typical course of severe acute and 
chronic arthritis (Fig. 2). In contrast, the rats injected with PG-APS and treated 
with mutanolysin developed a  mild acute arthritis that disappeared within 14 d 
with no subsequent appearance of inflammation over the period of observation 
(Fig.  2).  The  control  group  receiving  only enzyme displayed no  evidence of 
inflammation at any time. 
It is important to note that the rats given mutanolysin immediately after PG- 
APS developed a transient limb edema that reached a peak by 2-3 h and subsided 
by 9  h  (Fig.  2).  This response is identical to that previously reported (13) with 
the  injection  of fragments  of PG-APS  generated  by  in  vitro  digestion  with 
mutanolysin. This transient edema did not develop in either control group. 
A  separate experiment was performed for the histological evaluation of rats 
injected with an arthropathic dose of PG-APS and immediately thereafter with 
mutanolysin or  PBS.  The  histological changes observed  in the tarsal joints of 
non-enzyme-treated Lewis rats were similar to the changes previously reported 
to occur in Sprague-Dawley rats (1, 2), with the exception that the late destruction 
of subchondral bone and growth of new bone was much more extensive in Lewis 
rats. When active mutanolysin was injected immediately after PG-APS, the initial 
exudative and proliferative synovitis observed 3 d after injection was qualitatively 
similar in the treated and untreated groups (Figs. 3 and 4). At 7 d after injection 
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FIGURE 2.  The course of arthritis  in rats treated  with mutanolysin (M-l) intravenously 
immediately  after an intraperitoneal injection of an arthropathic dose of PG-APS. The control 
group received PG-APS i.p. and 0.4 ml of PBS i.v.; the experimental group received PG-APS 
i.p. and 0.4 ml M-1 (1 mg/ml) i.v. There were initially 18 rats in each group. Six rats from 
each group were killed at 2, 5, and 36 d after PG-APS injection for quantitation of cell wall 
in tissues (Table I). Clinical  joint scores (arthritis or edema) in this and subsequent figures are 
presented as the mean + SEM. The difference in arthritis scores  between groups was significant 
(P < 0.01) at all time points as calculated by the Student's t test. 1364  TREATMENT  OF  ARTHRITIS  IN  RATS WITH  MUTANOLYSIN 
FIGURE 3.  Tarsal joint of a control rat that received PG-APS followed  immediately  by PBS. 
Tissues were collected after 3 d. An acute exudative synovitis  was present. The joint space 
contained leukocytes  and fibrin. HE stained. × 100. 
the extent of the acute synovitis was less in the animals receiving mutanolysin. 
At  14 d  after injection of PG-APS the animals given mutanolysin showed very 
mild synovitis characterized by focal proliferation of synovial lining cells, focal 
areas of scarring  in  the  synovial stroma, and a  small number of mononuclear 
cells in the synovial tissues. This was in striking contrast to the active synovitis in 
the non-enzyme-treated control rats. Fig. 5 illustrates a normal-appearing joint 
tissue from an enzyme-treated rat 41  d  after injection of PG-APS. For contrast, 
the extensive proliferative erosive synovitis observed in the non-enzyme-treated 
animals at 41  d  after PG-APS injection is illustrated in Fig. 6. 
PG-APS  Arthritis  Is  Reversed  by  Mutanolysin  When  Administered  After  Acute 
Inflammation Has Been Established.  A  series of experiments were performed to 
determine  whether  mutanolysin could  effect the  course  of arthritis  after  the 
initiation of disease. In the first experiment, rats were injected intraperitoneally 
with an arthropathic dose of PG-APS and randomly divided into two groups. 24 
h  later,  experimental  rats  were  injected with  0.4  mg of mutanolysin, and the 
control group received 0.4  ml of PBS.  At the time of enzyme injection, acute 
arthritis was just beginning and was relatively mild. Acute arthritis continued to 
develop in enzyme-treated rats, but was significantly less severe than in control 
rats  (Fig.  7). Joint  disease resolved  in  enzyme-treated rats  by day  14,  and  no 
evidence of recurrence was observed through day 36.  Control rats went on to 
develop the typical pattern of chronic arthritis. JANUSZ ET  AL.  1365 
FIGURE 4.  Tarsal  joint of an experimental rat that received PG-APS followed  immediately 
by mutanolysin. Tissues were collected after 3 d. An acute exudative synovitis  was present. 
The joint space contained leukocytes  and fibrin. HE stained. X 100. 
In a second experiment, rats were injected with mutanolysin or PBS 3 d after 
receiving an arthropathic  dose of cell wall,  which is approximately the time of 
peak acute inflammation. Joint disease in the enzyme-treated rats was significantly 
less  than  in  the  control  group  within  48  h  after  treatment  and  eventually 
completely resolved (Fig.  8). Thus,  mutanolysin can reverse progression of cell 
wall-induced  arthritis  even  when  administration  is  delayed  until  severe joint 
disease has developed. 
Mutanolysin and PBS-treated rats described in Fig. 8 were examined histolog- 
ically 83  d  after  PG-APS  injection.  Rats  injected  with  PG-APS and  3  d  later 
given PBS showed erosive synovitis that had evolved to a stage characterized by 
widespread  destruction  of cartilage  and  bone,  extensive growth  of new bone 
with  marked  distortion  of the  normal  architecture  of the  tarsal  bones,  severe 
scarring of the synoviai tissue, and fibrous ankylosis of many of the joints. A few 
of  the joints  in  each  animal  were  still  involved  by  an  acute  exudative  and 
proliferative synovitis. Rats injected intraperitoneally with PG-APS and 3 d later 
given  mutanolysin  intravenously showed minimal  active inflammation  at  83  d, 
which consisted of focal areas of hyperplasia  of synovial lining  cells.  The  only 
indication  of previous erosive synovitis were a  few small areas where cartilage 
appeared to be replaced by fibrous tissue at the margin of the joint surfaces and 
focal areas of scarring in the synovial stroma. 
In a third experiment, mutanolysin or PBS was administered to rats 14 d after 1366  TREATMENT  OF  ARTHRITIS  IN  RATS  WITH  MUTANOLYS1N 
FIGURE 5.  Tarsal joint of an experimental rat that received PG-APS followed immediately 
by mutanolysin. Tissues were collected after 41  d. The joint space contained no exudate and 
the cartilage was intact. HE stained. ×  100. 
PG-APS  injection,  which  is  the  approximate  time  when  the  chronic  phase  of 
arthritis begins. After a slight initial increase, joint scores of mutanolysin-treated 
rats  declined,  and  became  significantly  lower  (P <  0.01)  than  those  of PBS- 
treated  rats  by day  30  after  PG-APS  injection  (Fig.  9).  Fig.  10  illustrates  the 
difference in clinical appearance between treated and untreated rats on day 44. 
Subsequently, only three  of the  nine  mutanolysin-treated  rats  demonstrated  a 
recurrent  episode  of  chronic  joint  disease.  In  two  of  these  three  rats,  the 
exacerbation  was  mild  and  short-lived.  The  third  rat  with  recurrent  arthritis 
developed  severe joint  disease  that  lasted  from  day  80  to  the  end  of  the 
experiment (day 127). 
A histological study was performed on day 127 on the rats whose clinical scores 
are shown in Fig. 9. Despite the clinical improvement in the enzyme-treated rats, 
erosive synovitis that  had resulted in synovial scarring and extensive distortion 
of the architecture  of the  tarsal  bones by abnormal  bone growth was equal  to 
that of PBS controls. This was not surprising, however, since by the time enzyme 
was administered  14 d after PG-APS, the rats had proceeded through the acute 
phase of arthritis.  Acute exudative, proliferative, and active erosive synovitis was 
observed in three of the enzyme-treated group and four of the untreated group 
at  127 d. 
Radiographic Data Confirms Clinical Assessment of  Arthritis.  Rats injected with 
PG-APS and  treated  with  mutanolysin  or PBS at  0,  3,  or  14 d  after  cell  wall JANUSZ ET  AL.  1367 
FIGURE  6.  Tarsal joint of a control rat that received PG-APS followed immediately by PBS. 
Tissues were collected after 41  d.  Extensive erosion of cartilage and subchondral bone was 
present. HE stained, x  100. 
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FIGURE  7.  Effect of mutanolysin  given  24  h  after  PG-APS on development of acute and 
chronic arthritis. Two groups of six rats were injected intraperitoneally with an arthropathic 
dose of PG-APS followed 24 h  later by an intravenous injection of PBS (O) or 0.4 mg of M-I 
i.v. (@). Statistically significant differences (P <  0.05)  between the groups were found at all 
time points after administration of M- 1. 
injection were x-rayed shortly before the termination  of each experiment.  Rats 
treated  with mutanolysin  up to 3  d  after PG-APS injection showed no chronic 
erosive arthritis,  while PBS-treated rats displayed the destructive changes asso- 
ciated  with  chronic  erosive  synovitis  (5).  Those  rats  that  were  treated  with 1368  TREATMENT  OF  ARTHRITIS IN  RATS  WITH  MUTANOLYS1N 
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FIGURE 8.  Effect of mutanolysin  given  at the peak  of acute arthritis on the further devel- 
opment of disease. Three groups of five rats were injected with an arthropathic dose of PG- 
APS i.p.  on day 0  plus 0.4 ml PBS on day 3  (0); 0.4  mg of M-1  on day 3  (7); or 0.4 mg of 
heat-inactivated M-1 on day 0 (O). Statistically significant differences (P < 0.02) between PBS- 
treated and M-l-treated rats were seen at all time points after day 5. The differences between 
PBS-treated rats and those treated with heat-inactivated M-1 were not significant at any time. 
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FIGURE 9.  Effect of mutanolysin given 14 d  after PG-APS on the development of chronic 
arthritis. A  control group of eight rats (e) was given an arthropathic dose of PG-APS i.p. 
followed 14 d later by an injection of PBS i.v. The experimental group (O) contained nine rats 
that were injected with an arthropathic dose of PG-APS i.p. and  14 d  later given 0.4 mg of 
M-1 i.v. 
mutanolysin  14  d  after  PG-APS  and  still  developed  clinical  and  histological 
arthritis also showed evidence of arthritis on x ray. 
Muramidase  Activity for Streptococcal  Cell  Wall Is Required  to Modify PG-APS- 
induced Arthritis.  As part of the experiment in which mutanolysin was given to 
rats  3  d  after  PG-APS,  0.4  mg of heat-inactivated  mutanolysin (boiled  for  10 
min)  was  injected  intravenously  into  a  group  of rats  immediately  after  the 
administration of an arthropathic dose of PG-APS. The results presented in Fig. 
8  demonstrate  that  heat-inactivated  M-1  does  not  reduce  PG-APS  arthritis. FIGURE  10.  (A)  Hind  limbs  of a  rat  with  PG-APS-induced  arthritis  44  d  after  PG-APS 
injection.  This  rat  had  a  clinical score of 8  and  is  from  the  control  group  (PBS  treated) 
described in Fig. 9. (B) Hind limbs of a  mutanolysin-treated rat 44 d  after PG-APS injection 
as described for the experimental group in Fig. 9. This rat had a clinical score of 0. 
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Histological  examination confirmed that  heat-inactivated mutanolysin had  no 
effect on the development of erosive synovitis. 
An  additional  control  experiment was  performed to  determine if hen  egg 
lysozyme injected in vivo could effect PG-APS-induced arthritis.  Hen egg lyso- 
zyme is a  basic protein  with muramidase activity, but  it  is  unable to degrade 
group A streptococcal cell wall in vitro (22-24).  Rats were injected intraperito- 
neally with an  arthropathic  dose  of PG-APS  and  randomly divided  into  two 
groups.  The  control  group  was  treated  with  0.4  mi  of PBS  i.v.,  while  the 
experimental group received 0.4 mg of hen egg lysozyme i.v. The results shown 
in  Fig.  11  demonstrate that  treatment of cell  wall-injected rats  in  vivo with 
iysozyme does not effect the course of arthritis. 
Mutanolysin  Can  Effect  the  PG-APS-induced  Inflammatory  Reaction  in  Other 
Tissues.  A  histological study of the liver, spleen, and mediastinal lymph nodes 
was performed on all rats whose  joint histology was described above. Rats injected 
with PG-APS and not treated with enzyme developed granulomatous lesions in 
the liver, spleen, and mediastinal lymph nodes. The process was extensive in the 
spleen by day 7 after PG-APS injection and in the liver and lymph nodes by day 
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FIGURE 11.  Course of arthritis in rats treated with lysozyme intravenously immediately after 
receiving PG-APS. Two groups of six rats were injected with an arthropathic dose of PG-APS 
i.p. followed immediately by 0.4 ml PBS i.v. (6) or 0.4 nag hen egg lysoz.yme i.v. (O). The 
differences between the two groups were not statistically significant at any ume. 
TABLE  I 
Effect of Mutanolysin on the Distribution of Cell Wall in Rat Tissue 
Control (cell wall i.p. plus PBS i.v.)  Experimental (cell wall i.p. plus M-1 i.v.) 
Day 2  Day 5  Day 36  Day 2  Day 5  Day 36 
Hind Limbs  0.70 +  0.21"  0.32 +  0.19  0.08 ±  0.06  3.7 ±  1.7  0.86 :t= 0.13  0.19 :!: 0.07 
Spleen  107±41  245+29  33±11  166+49  92±25  16±  1.7 
Liver  145+25  32±11  ND*  300±189  136:t=37  39±24 
Blood  1.7±0.68  0.11±0.09  0.07±0.01  2.3±0.94  0.30+0.07  <0.06 
* Mean +  SEM of PG-APS in micrograms per gram of tissue; five rats per group. 
No data. JANUSZ ET AL.  1371 
14. The initial reaction appeared to be the formation of granulomas consisting 
of focal collection of macrophages and giant cells associated with the presence of 
small numbers of neutrophils and lymphocytes. As the collection of inflammatory 
cells increased in size, the relative number of neutrophils increased in the central 
areas  of the  lesions  and  irregular  areas  of necrosis  developed  that  became 
surrounded by concentric layers of fibrous tissue infiltrated with neutrophils and 
mononuclear cells.  In contrast, no such changes were observed in rats treated 
with active mutanolysin immediately or 3 d after PG-APS injection. Granuloma- 
tous lesions did develop in  rats  treated with  mutanolysin  14  d  after PG-APS 
injection. A  more detailed description of the histology of this complex inflam- 
matory response and its relationship to the distribution and persistence of PG- 
APS in the reticuloendothelial tissues of Lewis rats will be reported elsewhere. 
Mutanolysin  Treatment  Does  Not  Cause  Elimination  of PG-APS from  the  Tis- 
sue.  The quantitative distribution of cell wall in rats injected intraperitoneally 
with PG-APS and immediately injected intravenously with PBS or mutanolysin 
is shown in  Table  I.  The rats  for this experiment are those whose course of 
arthritis is shown in Fig. 2.  On day 2,  5, and 36,  rats were sacrificed for assay. 
The hind limbs, liver, spleen, and blood from enzyme-treated animals contained 
quantities of PG-APS that equaled or appeared to exceed the amounts found in 
PBS-treated control rats. Therefore, it is unlikely that mutanolysin causes a rapid 
elimination of PG-APS from the limbs, liver, and spleen. 
Discussion 
The intravenous injection of a single dose of 0.4 mg of the muralytic enzyme 
mutanolysin profoundly altered  the  course  and  severity of PG-APS-induced 
arthritis,  even  when  the  enzyme was  given  after  the  inflammation was  well 
established. In rats that received mutanolysin up to 3 d after PG-APS, acute joint 
inflammation resolved and did not progress into chronic recurrent disease.  If 
treatment with the enzyme was delayed until 14 d after PG-APS, the severity of 
the recurrent chronic phase of arthritis was significantly reduced by clinical and 
radiological assessment, although active inflammation was evident in some spec- 
imens by histological examination. 
We originally hypothesized that  the mutanolysin would hasten clearance of 
tissue-bound PG-APS.  However, quantitative ELISA studies on tissue extracts 
failed to demonstrate that catabolism of PG-APS was significantly enhanced by 
enzyme treatment. In fact, more PG-APS was detected in the tissues of enzyme- 
treated  rats  than  in  PBS-treated  control  animals.  This  difference could  be 
accounted for by increased antibody binding of the enzyme-digested PG-APS in 
the ELISA assay due to the exposure of more epitopes. This was suggested by 
in  vitro  digestion  of PG-APS  with  mutanolysin,  which  resulted  in  enhanced 
ELISA detectability of the same degree as seen in Table I (unpublished obser- 
vations). 
An alternative hypothesis is  that mutanolysin modifies cell wall-induced ar- 
thritis by degrading PG-APS to polymers that still persist in tissue, but are of a 
size which is nonarthropathic. Previous studies (12,  13) have demonstrated that 
the polymer size of PG-APS is important for the production of chronic inflam- 
mation. PG-APS degraded in vitro with mutanolysin to fragments with a molec- 1372  TREATMENT  OF  ARTHRITIS  IN  RATS  WITH  MUTANOLYSIN 
ular weight of <5.0  x  106 was unable to induce arthritis by systemic injection 
(13). 
The evidence that PG-APS was degraded in vivo by mutanolysin consists of 
two observations: (a) Rats injected intravenously with mutanolysin immediately 
after an intraperitoneal injection of PG-APS developed a rapid transient edema 
in their limbs. The kinetics of edema development was the same as that seen in 
rats injected with PG-APS degraded to a small fragment size by mutanolysin in 
vitro (13).  (b) ELISA analysis of sucrose gradient fractions has shown that the 
proportion of small cell wall fragments in the tissues of mutanolysin-treated rats 
was greatly increased compared with PBS-treated animals (Janusz, M.J., R. A. 
Eisenberg, and J. H. Schwab, manuscript in preparation). 
An extension of our current hypothesis regarding the reduction of PG-APS- 
induced  arthritis  by  mutanolysin  is  that  digested  PG-APS  fragments  could 
interfere with the larger arthropathic cell wall fragments.  For example, small 
nonarthropathic PG-APS fragments may compete with arthropathic PG-APS for 
binding sites on synovial tissue or soluble proteins such as complement. This 
hypothesis is attractive, as it would require only a small percentage of the total 
cell wall injected to be degraded to small fragments in order to suppress arthritis. 
Also pertinent is recent work (25) demonstrating that muramyl dipeptide (MDP) 
has antiinflammatory activity in several models of acute inflammation in rats and 
mice. 
It is conceivable that the effect of mutanolysin on PG-APS-induced arthritis is 
not.due to its specific enzymatic activity. However, heat-inactivated mutanolysin 
did not reduce the severity of arthritis in PG-APS-injected rats. In addition, hen 
egg lysozyme, which is a  cationic muralytic enzyme but is unable to digest the 
cell wall of group A  streptococci, did not reduce PG-APS-induced arthritis.  In 
another model of chronic intermittent inflammation, enzymes have been shown 
to mediate in vivo suppression of activity. For example (26), incubation of group 
A cell wall in vitro with the culture supernatant of Streptomyces albus results in 
digestion of the cell wall and a  loss of the ability to produce dermal lesions in 
rabbit skin. In addition, injection of filtrates ofS. albus or group C streptococcal 
phage-associated lysin directly into a cell wall injection site in rabbit skin results 
in a decrease in the severity and duration of dermal lesions (27). 
The demonstration that mutanolysin has a profound effect in vivo on PG-APS- 
induced  arthritis  may be  significant  for  the  study  of inflammation,  since  it 
provides a  unique  situation  in  which the phlogistic agent can be rapidly and 
specifically inactivated in vivo while the inflammatory response is evolving. The 
immediate usefulness of mutanolysin is as a tool to dissect various aspects of PG- 
APS-induced arthritis in the rat. If the model of cell wall-induced arthritis proves 
to  be  related  to  human arthritides,  this  approach  may also  be  useful in  the 
analysis  of the  etiology  and  mechanisms  of joint  destruction,  or  even  as  a 
therapeutic modality. 
Summary 
A  single intravenous injection into rats  of 0.4  mg of the muralytic enzyme 
mutanolysin, given as long as 3 d  after an arthropathic dose of peptidoglycan- 
polysaccharide polymers derived from group A streptococci (PG-APS), resulted JANUSZ ET  AL.  1373 
in a  complete resolution of acute arthritis and the prevention of chronic joint 
disease.  When administration of mutanolysin was delayed until  14 d  after the 
injection of PG-APS, a  great reduction in the severity of chronic inflammation 
was still observed. Quantitation of the amount of PG-APS present in the limbs, 
spleen, and liver by a solid phase enzyme-linked immunoassay indicated that the 
tissues of mutanolysin-treated rats contained as much PG-APS as tissues of PBS- 
treated control rats. In addition, rats treated with mutanolysin immediately after 
receiving  an  intraperitoneal  injection  of PG-APS  developed  a  transient  limb 
edema similar to that seen in rats after the injection of PG-APS digested to a 
small fragment size in vitro with mutanolysin. We hypothesize that mutanolysin 
acts in  vivo by degrading PG-APS  to small  fragments that persist  but are  no 
longer arthropathic. 
Received for publication  lO July 1984. 
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